DelveInsight’s “Hereditary Angioedema Pipeline Insight, 2025” report provides comprehensive insights about 20+ companies and 30+ pipeline drugs in the Hereditary Angioedema pipeline landscape. It covers the Hereditary Angioedema pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hereditary Angioedema pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Hereditary Angioedema Pipeline. Dive into DelveInsight’s comprehensive report today! @ https://www.delveinsight.com/sample-request/hereditary-angioedema-pipeline-insight

Key Takeaways from the Hereditary Angioedema Pipeline Report

• On January 14, 2026- Astria Therapeutics Inc. announced a Phase 3 multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating the safety and efficacy of subcutaneous administration of navenibart in adult and adolescent participants with type 1 or type 2 hereditary angioedema (HAE). The goal of this clinical trial is to evaluate the efficacy and safety of navenibart compared to placebo in preventing HAE attacks in participants with HAE.
• On December 05, 2025, Pharvaris Netherlands B.V. conducted a Phase 3, multicenter, 3-part study, with 2 randomized, double-blind, placebo-controlled parts and an open-label extension part, to evaluate the efficacy and safety of orally administered deucrictibant XR tablet for prophylaxis, and deucrictibant IR capsule for on-demand treatment of angioedema attacks in adult participants aged ≥ 18 years with AAE-C1INH.
• On December 03, 2025 — Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company focused on developing oral bradykinin B2 receptor antagonists to address unmet needs in bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), reported pivotal findings from the RAPIDe-3 study demonstrating the differentiated potential of deucrictibant for on-demand treatment of HAE attacks. Results from this first pivotal Phase 3 trial will support marketing authorization submissions, targeted to begin in the first half of 2026.
• On December 02, 2025, Intellia Therapeutics announced a Phase 3 study aims to evaluate the efficacy and safety of NTLA-2002 compared to placebo in participants with HAE. This is a multinational, multicenter, double-blind, placebo-controlled study in which approximately 60 participants will be randomized in a 2:1 ratio to receive a single IV infusion of NTLA-2002 or placebo. After the Primary Observation Period (Week 1 through Week 28), participants will have the option to receive a blinded, single IV infusion of the opposite treatment.
• DelveInsight’s Hereditary Angioedema pipeline report depicts a robust space with 20+ active players working to develop 30+ pipeline therapies for Hereditary Angioedema treatment.
• The leading Hereditary Angioedema Companies such as Corcept Therapeutics, BioCryst Pharmaceuticals, KalVista Pharmaceuticals, Pharvaris, BioMarin Pharmaceutical, Ionis Pharmaceuticals, Inc., and Intellia Therapeutics and others.
• Promising Hereditary Angioedema Pipeline Therapies such as NTLA-2002, Donidalorsen, STAR-0215, Garadacimab, TAK-743 300 mg, ADX-324, CSL312, TAK-667, Lanadelumab, KVD900 and others.

Stay ahead with the most recent pipeline outlook for Hereditary Angioedema. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Hereditary Angioedema Treatment Drugs

The Hereditary Angioedema Pipeline Report provides a disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The Hereditary Angioedema Pipeline Report also highlights the unmet needs with respect to Hereditary Angioedema.

Hereditary Angioedema Overview

Hereditary angioedema is a disorder characterized by recurrent episodes of severe swelling (angioedema). The most common areas of the body to develop swelling are the limbs, face, intestinal tract, and airway. Minor trauma or stress may trigger an attack, but swelling often occurs without a known trigger. Episodes involving the intestinal tract cause severe abdominal pain, nausea, and vomiting.

Hereditary Angioedema Emerging Drugs Profile

• KVD900: KalVista Pharmaceuticals

KVD900 is a candidate from our oral portfolio of plasma kallikrein inhibitors. It exhibits high solubility and high permeability and is uniquely suited for on-demand treatment of HAE attacks, with rapid uptake into the plasma and high plasma concentrations. Data in phase II clinical trial for KVD900 is anticipated in the fourth quarter of 2020. Currently, the drug is inthe Phase III stage of development for the treatment of Hereditary angioedema.

• PHA121: Pharvaris

PHA121 is a novel small molecule with drug-like properties. In preclinical studies, PHA121 demonstrates highly potent and selective competitive antagonism of the B2 receptor, and shows rapid and potent activity on oral dosing in a bradykinin-mediated disease model. It is currently in phase II stage of development.

• BMN 331: BioMarin Pharmaceutical

BMN 331 is a gene therapy product candidate for HAE. It is currently in Phase I stage of development.

Explore groundbreaking therapies and clinical trials in the Hereditary Angioedema Pipeline. Access DelveInsight’s detailed report now! @ New Hereditary Angioedema Drugs

The Hereditary Angioedema Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Hereditary Angioedema with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hereditary Angioedema Treatment.
• Hereditary Angioedema Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Hereditary Angioedema Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hereditary Angioedema market

Hereditary Angioedema Companies

Corcept Therapeutics, BioCryst Pharmaceuticals, KalVista Pharmaceuticals, Pharvaris, BioMarin Pharmaceutical, Ionis Pharmaceuticals, Inc., and Intellia Therapeutics and others.

Hereditary angioedema pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Topical

Hereditary Angioedema Products have been categorized under various Molecule types such as

• Gene therapies
• Small molecule
• Vaccines
• Polymers
• Peptides
• Monoclonal antibodies

Unveil the future of Hereditary Angioedema Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Hereditary Angioedema Market Drivers and Barriers

Scope of the Hereditary Angioedema Pipeline Report

• Coverage- Global
• Hereditary Angioedema Companies- Corcept Therapeutics, BioCryst Pharmaceuticals, KalVista Pharmaceuticals, Pharvaris, BioMarin Pharmaceutical, Ionis Pharmaceuticals, Inc., and Intellia Therapeutics and others.
• Hereditary Angioedema Pipeline Therapies- NTLA-2002, Donidalorsen, STAR-0215, Garadacimab, TAK-743 300 mg, ADX-324, CSL312, TAK-667, Lanadelumab, KVD900 and others.
• Hereditary Angioedema Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Hereditary Angioedema Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Hereditary Angioedema Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Hereditary Angioedema Companies, Key Products and Unmet Needs

Table of Contents

1. Introduction
2. Executive Summary
3. Hereditary angioedema: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Hereditary angioedema – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Hereditary angioedema Collaboration Deals
9. Late Stage Products (Phase III and NDA)
10. KVD900: KalVista Pharmaceuticals
11. Mid Stage Products (Phase II)
12. PHA121: Pharvaris
13. Early Stage Products (Phase I)
14. BMN 331: BioMarin Pharmaceutical
15. Pre-clinical and Discovery Stage Products
16. Drug Name: Company Name
17. Inactive Products
18. Hereditary angioedema Key Companies
19. Hereditary angioedema Key Products
20. Hereditary angioedema- Unmet Needs
21. Hereditary angioedema- Market Drivers and Barriers
22. Hereditary angioedema- Future Perspectives and Conclusion
23. Hereditary angioedema Analyst Views
24. Hereditary angioedema Key Companies
25. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/hereditary-angioedema-pipeline-insight